Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Boston, United States
Countries of investment
  • USA
Investment stages
  • Seed
  • Series A
Industries
  • Biotechnology
  • Life Sciences
  • MedTech
  • Pharma
About
T.Rx Capital, founded by experienced biotech investors, provides scientific and financial expertise to help startups progress from lab discovery to clinical validation. The firm brings strategic partnerships, advisory networks, and early institutional support tailored to high-risk, high-reward biotech ventures.
Min check size
$500K
Max check size
$10M
Fund size
NPS

Investment Thesis

Specializes in biotech and therapeutic innovation at seed and Series A. Focuses on platform technologies and novel therapeutics with strong scientific foundations.
Lead investor
Co Invest
Number of exits
Preferred contact method

T.Rx Capital Contacts Information

Primary contact

Secondary contact

Team

Robert Langer – Executive Chairman & Chair of SAB; Dr. Kwesi Frimpong-Boateng – Co-Founder & Managing Partner; Michael Langer – Co-Founder & Managing Partner; Dr. Corey McCann – Co-Founder & Managing Partner; Dr. Liz Kwo – Venture Partner; Dr. Debbie W. Lin – Venture Partner; Dan O’Neill – Fractional COO; Anita DiFazio – Director of Finance & Accounting; Pranav Seshadri – Analyst

Portfolio

Recuro

Zus

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp